| Identification | Back Directory | [Name]
BML-275 | [CAS]
1219168-18-9 | [Synonyms]
CS-1883
Dorsomorph
BML-275(2HCL)
Compound C 2HCl
Dorsomorphin HCl
BML-275,Compound C
BML-275 dihydrochloride
Dorsomorphin-2HCl
BML-275
BML-275 Dorsomorphin 2HCL
Compound C dihydrochloride
dorsoMorphin (Hydrochloride)
DORSOMORPHIN (COMPOUND C) 2HCL
Dorsomorphin 2HCl
(BML-275 2HCl)
BML-275; COMPOUND C; BML275; BML 275
Dorsomorphin(BML-275)dihydrochloride
DORSOMORPHIN 2HCL;BML275.HCL;COMPOUND C
DorsoMorphin, Dihydrochloride Salt, >99%
Dorsomorphin (Compound C) dihydrochloride
6-[4-(2-PIPERIDIN-1-YLETHOXY)PHENYL]-3-PYRIDIN-4-YLPYRAZOLO[1,5-A]PYRIMIDINE;DIHYDROCHLORIDE
6-[4-[2-(1-Piperidinyl)ethoxy]phenyl]-3-(4-pyridinyl)pyrazolo[1,5-a]pyrimidine hydrochloride (1:2)
BML-275;COMPOUND C;BML275;BML 275;BML-275 DIHYDROCHLORIDE;COMPOUND C DIHYDROCHLORIDE;BML275 DIHYDROCHLORIDE;BML 275 DIHYDROCHLORIDE
6-[4-[2-(1-Piperidinyl)ethoxy]phenyl]-3-(4-pyridinyl)pyrazolo[1,5-a]pyrimidine hydrochloride (1:2) Dorsomorphin 2HCl | [Molecular Formula]
C24H27Cl2N5O | [MDL Number]
MFCD11112197 | [MOL File]
1219168-18-9.mol | [Molecular Weight]
472.41 |
| Chemical Properties | Back Directory | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
insoluble in EtOH; insoluble in H2O; ≥11.34 mg/mL in 0.9% NS ; ≥39.93 mg/mL in DMSO:H2O=2:1 ; ≥5.91 mg/mL in DMSO | [form ]
Light yellow powder solid. | [color ]
Yellow | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Description]
Dorsomorphin (hydrochloride) is a potent, reversible inhibitor of AMP kinase (AMPK; Ki = 109 nM) that does not exhibit significant activity on structurally related kinases, including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin can also dose-dependently inhibit the bone morphogenetic protein type 1 receptors ACTR-I (ALK2), BMPR-IA (ALK3), and BMPR-IB (ALK6). Independent of AMPK inhibition, dorsomorphin, at 10 μM, has additionally been shown to downregulate the Akt/mTOR pathway to induce autophagy in U251 human glioma cells. | [Uses]
Dorsomorphin is an AMP-activated kinase (AMPK) inhibitor. Dorsomorphin selectively inhibits the bone morphogenetic protein (BMP) type I receptors ALK2, ALK3 and ALK6 and thus blocks BMP-mediated SMAD1/5/8 phosphorylation, target gene transcription and osteogenic differentiation. Dorsomorphin has shown to increase cisplatin-induced apoptosis, which was associated with hyper-induction of the tumor suppressor p53. | [storage]
Room temperature (desiccate) |
|
|